Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: Examining organisms with multiple types of β-lactamases

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 1, 2012, Pages 258-270

  Louie, Arnold ^a,e   Castanheira, Mariana ^b   Liu, Weiguo ^a,e   Grasso, Caroline ^a   Jones, Ronald N ^b   Williams, Gregory ^c,d   Critchley, Ian ^c,d   Thye, Dirk ^c,d   Brown, David ^a,e   VanScoy, Brian ^a,e   Kulawy, Robert ^a,e   Drusanoa, G L ^a,e  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b JMI LABORATORIES   (United States)

^c Cerexa Inc   (United States)

^d FOREST RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM; BETA LACTAMASE; BETA LACTAMASE AMPC; BETA LACTAMASE CTX M; BETA LACTAMASE KPC 2; BETA LACTAMASE SHV; BETA LACTAMASE TEM 1; CEFTAROLINE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL CELL; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CELL KILLING; ENTEROBACTER CLOACAE; ENZYME INHIBITION; HOLLOW FIBER REACTOR; KLEBSIELLA PNEUMONIAE; MUTATION RATE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; AZABICYCLO COMPOUNDS; BACTERIAL PROTEINS; BETA-LACTAMASES; CEPHALOSPORINS; CHROMATOGRAPHY, LIQUID; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; TANDEM MASS SPECTROMETRY;

EID: 84455161611     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05005-11     Document Type: Article

References (10)

1. Bilello JA, Bauer G, Dudley MN, Cole GA, Drusano GL. 1994. Effect of 2′,3′-didehydro-3′-deoxythymidine in an in vitro hollow fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies. Antimicrob. Agents Chemother. 38:1386-1391. (Pubitemid 24170724)
2. Blaser J, Stone BB, Groner MC, Zinner SH. 1987. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob. Agents Chemother. 31:1054-1060. (Pubitemid 17099578)
3. Borgonovi M, et al. 2008. Importance of NXL104 pharmacokinetics (PK) in the pharmacodynamics (PD) of ceftazidime+ NXL104 combinations in an in vitro hollow fiber infection model, abstr. A-023. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother./46th Meet. Infect. Dis. Soc. Am.
4. Drusano GL, et al. 2001. Hollow fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable. J. Infect. Dis. 183: 1126-1129. (Pubitemid 32230964)
5. Drusano GL, et al. 2002. Pharmacodynamics of abacavir in an in vitro hollow fiber model system. Antimicrob. Agents Chemother. 46:464-470. (Pubitemid 34087197)
6. Gumbo T, et al. 2004. Selection of a moxifloxacin dose that suppresses Mycobacterium tuberculosis resistance by use of an in vitro pharmacodynamic infection model and mathematical modeling. J. Infect. Dis. 190: 1642-1651. (Pubitemid 39411014)
7. Jacoby G. 2009. 2009. AmpC β-lactamases. Clin. Microbiol. Rev. 22: 664-689.
8. Mendona̧ N, Leitão J, Manageiro V, Ferreira E, Caniça M. 2007. Spread of extended-spectrum beta-lactamase CTX-M-producing Escherichia coli clinical isolates in community and nosocomial environments in Portugal. Antimicrob. Agents Chemother. 51:1946-1955.
9. Smith Moland E, et al. 2003. Plasmid-mediated, carbapenemhydrolyzing beta-lactamase, KPC-2, in Klebsiella pneumoniae isolates. J. Antimicrob. Chemother. 51:711-714.
10. Strayer AH, et al. 1994. Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection. Antimicrob. Agents Chemother. 38:2351-2356. (Pubitemid 24304229)